Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study.
| Title: | Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. |
|---|---|
| Authors: | Sennesael AL; Louvain Drug Research Institute, Clinical Pharmacy Research Group, Université catholique de Louvain, Brussels, Belgium.; Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Department of Pharmacy, University of Namur, Namur, Belgium.; Larock AS; CHU UCL Namur, Namur Thrombosis and Hemostasis Center, Department of Pharmacy, Université catholique de Louvain, Yvoir, Belgium.; Devalet B; CHU UCL Namur, Namur Thrombosis and Hemostasis Center, Department of Hematology, Université catholique de Louvain, Yvoir, Belgium.; Mathieux V; CHU UCL Namur, Namur Thrombosis and Hemostasis Center, Department of Hematology, Université catholique de Louvain, Yvoir, Belgium.; Verschuren F; Institute of Experimental and Clinical Research, Cliniques Universitaires Saint-Luc, Department of Emergency Medicine, Université catholique de Louvain, Brussels, Belgium.; Muschart X; CHU UCL Namur, Department of Emergency Medicine, Université catholique de Louvain, Yvoir, Belgium.; Dalleur O; Louvain Drug Research Institute, Clinical Pharmacy Research Group, Université catholique de Louvain, Brussels, Belgium.; Cliniques Universitaires Saint-Luc, Department of Pharmacy, Université catholique de Louvain, Brussels, Belgium.; Dogné JM; Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Department of Pharmacy, University of Namur, Namur, Belgium.; Spinewine A; Louvain Drug Research Institute, Clinical Pharmacy Research Group, Université catholique de Louvain, Brussels, Belgium.; CHU UCL Namur, Namur Thrombosis and Hemostasis Center, Department of Pharmacy, Université catholique de Louvain, Yvoir, Belgium. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2018 Jul; Vol. 84 (7), pp. 1544-1556. Date of Electronic Publication: 2018 Apr 17. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study |
| Language: | English |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Wiley-Blackwell; Original Publication: London, Macmillan Journals Ltd. |
| MeSH Terms: | Anticoagulants/*adverse effects ; Gastrointestinal Hemorrhage/*prevention & control ; Intracranial Hemorrhages/*prevention & control ; Thromboembolism/*prevention & control; Anticoagulants/administration & dosage ; Atrial Fibrillation/prevention & control ; Emergency Service, Hospital/statistics & numerical data ; Gastrointestinal Hemorrhage/chemically induced ; Gastrointestinal Hemorrhage/epidemiology ; Hospitalization/statistics & numerical data ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/epidemiology ; Stroke/prevention & control ; Thromboembolism/chemically induced ; Thromboembolism/epidemiology ; Vitamin K/antagonists & inhibitors ; Administration, Oral ; Aged ; Aged, 80 and over ; Continuity of Patient Care ; Female ; Humans ; Male ; Patient Education as Topic ; Prospective Studies |
| Abstract: | Aims: To determine the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs), and to explore contributing factors to preventable ADRs. Results were compared with vitamin K antagonists (VKAs).; Methods: We conducted a prospective observational study in the emergency departments of two teaching hospitals from July 2015 to January 2016. Patients admitted with a thrombotic or bleeding event while under DOAC or VKA were included. Four independent reviewers assessed causality, seriousness and preventability of ADRs using pilot-tested scales. For cases of serious and potentially preventable ADRs, we performed semi-structured interviews with general practitioners to identify contributing factors to ADRs. The primary outcome was the proportion of serious ADRs that were potentially preventable.; Results: The analysis included 46 DOAC and 43 VKA patients (median age 79 years). Gastrointestinal (n = 34) and intracranial (n = 16) bleedings were the most frequent ADRs. Results were that 53% of DOAC- and 61% of VKA-related serious ADRs were deemed potentially preventable. Prescribing issues and inadequate monitoring were frequent for DOAC and VKA respectively. We identified many causes of preventable ADRs that applied to all oral anticoagulants, such as pharmacodynamic drug interactions and lack of communication.; Conclusions: More than half of serious ADRs were potentially preventable for both DOACs and VKAs. Interventions focusing on prescribing, patient education and continuity of care should help improve the use of DOACs in practice.; (© 2018 The British Pharmacological Society.) |
| References: | Int J Gen Med. 2017 Mar 10;10:87-94. (PMID: 28331354); Int J Clin Pharm. 2015 Aug;37(4):656-68. (PMID: 25822042); Chest. 2017 Jul;152(1):81-91. (PMID: 28219635); Jt Comm J Qual Patient Saf. 2017 Jun;43(6):299-307. (PMID: 28528624); Thromb Haemost. 2016 Jan;115(2):257-70. (PMID: 26466666); Lancet. 2002 Apr 20;359(9315):1373-8. (PMID: 11978334); Ann Intern Med. 2013 Jun 18;158(12):861-8. (PMID: 23778903); Thromb J. 2015 May 26;13:22. (PMID: 26124699); Am J Med. 2011 Dec;124(12):1136-42. (PMID: 22114827); Europace. 2016 Jan;18(1):151-5. (PMID: 26462697); Am J Med. 2007 Jun;120(6):539-44. (PMID: 17524757); J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. (PMID: 24685669); JAMA. 2016 Nov 22;316(20):2115-2125. (PMID: 27893129); Br J Clin Pharmacol. 2017 May;83(5):1134-1140. (PMID: 27905143); Arch Intern Med. 2008 Sep 22;168(17):1890-6. (PMID: 18809816); Br J Haematol. 2013 Oct;163(2):160-7. (PMID: 23937286); Blood. 2014 Aug 7;124(6):955-62. (PMID: 24859362); JAMA Ophthalmol. 2015 Oct;133(10):1184-6. (PMID: 26111247); Eur Heart J. 2014 Jul 21;35(28):1873-80. (PMID: 24658769); J Am Heart Assoc. 2016 Feb 23;5(2):. (PMID: 26908401); N Engl J Med. 2013 Jun 20;368(25):2440-2. (PMID: 23782198); Arch Intern Med. 2011 Jul 25;171(14):1285-6. (PMID: 21788545); BMJ. 1998 Apr 11;316(7138):1154-7. (PMID: 9552960); J Am Geriatr Soc. 2015 Nov;63(11):2227-46. (PMID: 26446832); Clinicoecon Outcomes Res. 2014 Dec 03;6:505-14. (PMID: 25506231); Clin Pharmacol Ther. 1981 Aug;30(2):239-45. (PMID: 7249508); Circulation. 2016 Jan 26;133(4):352-60. (PMID: 26673560); Eur Heart J. 2016 Apr 7;37(14):1145-53. (PMID: 26330425); Circulation. 2008 Oct 28;118(18):1894-909. (PMID: 18836135); CMAJ. 2017 Jan 9;189(1):E4-E10. (PMID: 28246253); Int J Qual Health Care. 2013 Dec;25(6):648-55. (PMID: 24141014); Circulation. 2007 May 29;115(21):2689-96. (PMID: 17515465); Lancet. 2016 Aug 20;388(10046):806-17. (PMID: 27560276); N Engl J Med. 2012 Mar 1;366(9):864-6. (PMID: 22375994); Ann Intern Med. 2015 Sep 1;163(5):382-5. (PMID: 26121536); Drug Saf. 2008;31(6):545-56. (PMID: 18484788); Thromb Res. 2015 Dec;136(6):1190-4. (PMID: 26545315); Br J Clin Pharmacol. 2007 Feb;63(2):136-47. (PMID: 16803468); Am Heart J. 2016 Sep;179:77-86. (PMID: 27595682); Am J Emerg Med. 2015 Mar;33(3):475.e1-5. (PMID: 25218622); Br J Clin Pharmacol. 2018 Jul;84(7):1544-1556. (PMID: 29522647); J Am Coll Cardiol. 2015 Dec 1;66(21):2271-2281. (PMID: 26610874); Europace. 2016 Nov;18(11):1609-1678. (PMID: 27567465); J Intern Med. 1990 Aug;228(2):83-90. (PMID: 2394974); JAMA. 2007 Feb 28;297(8):831-41. (PMID: 17327525); J Am Geriatr Soc. 2017 Jan;65(1):185-193. (PMID: 27910092); J Clin Epidemiol. 1992 Oct;45(10):1045-51. (PMID: 1474400); Europace. 2015 Oct;17(10):1467-507. (PMID: 26324838); JAMA. 2003 Mar 5;289(9):1107-16. (PMID: 12622580); Eur Heart J. 2015 Sep 1;36(33):2239-45. (PMID: 25971288); Int J Cardiol. 2017 Jan 15;227:261-266. (PMID: 27843050); Ann Pharmacother. 2014 Oct;48(10):1258-68. (PMID: 24982310); N Engl J Med. 2016 Mar 17;374(11):1053-64. (PMID: 26981935); JAMA Intern Med. 2015 Oct;175(10):1608-9. (PMID: 26237648); N Engl J Med. 2011 Nov 24;365(21):2002-12. (PMID: 22111719); J Emerg Med. 2014 Jun;46(6):831-2. (PMID: 24199727); Drugs Aging. 2006;23(7):579-86. (PMID: 16930086) |
| Contributed Indexing: | Keywords: adverse drug reactions; medication errors; oral anticoagulants; patient safety; qualitative research |
| Substance Nomenclature: | 0 (Anticoagulants); 12001-79-5 (Vitamin K) |
| Entry Date(s): | Date Created: 20180310 Date Completed: 20190909 Latest Revision: 20220330 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6005616 |
| DOI: | 10.1111/bcp.13580 |
| PMID: | 29522647 |
| Database: | MEDLINE |
Journal Article; Multicenter Study; Observational Study